Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reaching Protein Target with SmofKabiven extra Nitrogen Versus Olimel N9E in Early Acute Critical Illness
2017-001972-46Phase 4Terminated
- Sponsor
- Fresenius Kabi
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of SmofKabiven Peripheral in None (2 arms), sponsored by Fresenius Kabi. Primary endpoint: Protein intake during 5-day treatment period. Started Nov 2018; status: terminated.
02
Drugs
SmofKabiven Peripheral
Beyond the preview
Go deeper on 2017-001972-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001972-46.